Tempest Therapeutics, Inc. (TPST) Misses Q2 EPS by 179c

Tempest Therapeutics, Inc. (NASDAQ: TPST) reported Q2 EPS of ($2.07), $1.79 worse than the analyst estimate of ($0.28).

For earnings history and earnings-related data on Tempest Therapeutics, Inc. (TPST) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• RBC Capital Downgrades Bucher Industries AG (BUCN:SW) (BCHHF) to Sector Perform
• Sodexo (SW:FP) (SDXAY) PT Raised to EUR53 at Deutsche Bank